The cornerstone of a well-functioning market is competition. President Biden’s Executive Order 14036, “Promoting Competition in the American Economy” identified a lack of competition as a key driver for problems across economic sectors.
Biological Products & Biosimilars
Reports
Displaying 1 - 4 of 4. 10 per page. Page 1.
Advanced SearchASPE Issue Brief
Medicare Part B Drugs: Trends in Spending and Utilization, 2008-2021
The U.S. Department of Health and Human Services (HHS), Office of the Assistant Secretary for Planning and Evaluation (ASPE) released new research on spending and utilization trends of Medicare Part B drugs, drugs administered in physicians' office or hospital outpatient departments rather than being purchased at the pharmacy counter or by mail order.
ASPE Issue Brief
Trends in Prescription Drug Spending, 2016-2021
High prescription drug costs are a leading concern among Americans. Americans pay higher prices for prescription drugs than any other country in the world, with prescription drug prices in the U.S. more than 2.5 times as high as those in other similar high-income nations.
Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey
This study presents the findings of a national survey of physicians about their knowledge of biosimilar biological products as well as the impact of biological product naming conventions on prescriber choice.
Related Products